NNon–small cell lung cancer (NSCLC)
Conditions
Interventions
EGFR-TKI Resistant Group / EGFR-TKI Sensitive Group:NA
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed non–small cell lung cancer (NSCLC) with established TNM staging; 2. Previously treated with or currently receiving first-line EGFR-TKI therapy; 3. Age >=18 years with an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0–2; 4. Signed informed consent and agreed to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Concurrent or recent systemic anticancer therapies other than EGFR-TKIs; 2. Severe hepatic or renal impairment, or significant neurological or psychiatric disorders; 3. Presence of another primary malignancy or existing extrapulmonary metastases from lung cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-Methylnicotinamide (1-MNA), 1-Methyl-6-oxo-3-pyridinecarboxamide (2-PYR), Nicotinamide (NAM), and Nicotinamide Mononucleotide (NMN).; | — |
Countries
China
Contacts
Public ContactMantang Qiu
Peking University People's Hospital
Outcome results
None listed